Home » Human Multiple Myeloma (MM) Cancer Stem Cell - Frozen Vial
Human Multiple Myeloma (MM) Cancer Stem Cell - Frozen Vial
Catalog Number : 36111-39
Availability : In Stock
Price : $550.00

Related Products

  • Description
  • Publication
  • Documents

Human Multiple Myeloma (MM) Cancer Stem Cell - Frozen Vial

Also Avaliable as:

T25 plated cells $550.00 shipped at room temperature. Cat# 36111-39-T25
T75 plated cells $750.00 shipped at room temperature. Cat# 36111-39-T75

T150 plated cells $2500.00 shipped at room temperature. Cat#36111-39-T150 T225 plated cells $5500.00 shipped at room temperature. Cat#36111-39-T225

120 Population doublings or up to 12 passages.

One million viable cells upon thawing of frozen cells, frozen vial of cells shipped in dry-ice.

This product would require pre-coated flasks with Human Multiple Myeloma (MM) Cancer Stem Cell Extra-cellular Matrix Cat# E36111-39 and Human Multiple Myeloma (MM) Cancer Stem Cell Media with Serum Cat# M36111-39S and for serum free conditions Cat# M36111-39 is required provided the cells are weaned off the serum, as indicated in their specified protocol provided with purchase of these cells.

In order to freeze these cells, the freezing media recommended for this product is Cat# M36111-39FM.


Cell Cultures from single donors, 1000 different cell cultures available, please indicate which lots you require from the 1000 donors.

Source: Human Bone Marrow.

Positive Markers: CD44, CD133, SSEA 3/4, Oct4, Tumorigenicity (<1000 cells), Alkaline Phosphatase, Telomerase, Aldehyde Dehydrogenase, CD19, CD20, CD34 mi RNA 1246 &1308, CD138+/-, CD27  

For non-academic use, please inquire for pricing.

Cells are only guaranteed with purchase of Celprogen Media, Extra Cellular Matrix, Trypsin EDTA, 1X PBS, and freezing media for the appropriate cell culture, for 30 days from the date of shipment.


1000 individual donors are fully characterized proprietary patient-derived xenografts (PDX) representing all major histotypes and capturing tumor diversity.

Subcutaneous, orthotopic and disseminated models.  Extensive molecular and pharmacological characterization as well as information on patients' pretreatment to help you select the most appropriate model.

Integrated approach: use the same PDX models and/or the corresponding cell line in 2D/3D screening assays and follow-up in vivo studies, identify biomarkers predicting tumor sensitivity for your compound.

Individually tailored study designs: proof of concept, dose level and schedule optimization, combinations, biomarker identification, etc.